Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

BMS designs dual PPARalpha/gamma activators for metabolic disorders

Aug. 22, 2007

Clinical candidate NYP Y5 antagonist discovered at Banyu

Aug. 22, 2007

Novel PPARalpha/gamma agonists improve blood glucose and lipid profiles in animals

Aug. 22, 2007

Thymoglobulin to be studied in new onset type 1 diabetes

Aug. 22, 2007

Phase III trial reveals phenylalanine reductions with sapropterin

Aug. 22, 2007

Positive results for Novo Nordisk's phase III studies of liraglutide

Aug. 22, 2007

XOMA-052 to enter the clinic for the treatment of type 2 diabetes

Aug. 21, 2007

EMEA accepts Jerini's marketing application for icatibant in HAE

Aug. 21, 2007

Oramed successfully completes oral insulin phase Ia trial

Aug. 21, 2007

Bone primary cilia: a potential target to prevent bone loss

Aug. 21, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...